Domestic market price of giritinib: How much does each box cost?
Gilitinib is a targeted therapy for a specific type of acute myeloid leukemia (AML). It is mainly used to treat relapsed or refractory AML patients with FLT3 mutations. FLT3 is an important receptor tyrosine kinase, and its mutation can lead to uncontrolled cell proliferation, so treatment targeting FLT3 is particularly important. Giritinib inhibits the activity of FLT3, thereby reducing the growth and survival of cancer cells and improving patients' quality of life and survival.

In China, the original drug of giritinib has been officially launched, but because it has not yet been included in medical insurance, many patients face greater financial pressure. According to market data, the current common specifications of gilitinib are 40mg tablets, and each box usually contains 21 tablets, packed in two plates. The price of this specification is about more than 20,000 yuan, and the specific price varies by region and drug store. Without medical insurance reimbursement, this cost is a significant burden for many patients, especially in the case of long-term treatment, where the overall cost of treatment may increase significantly.
In addition to the original drug, some patients also choose to purchase the Hong Kong version of giritinib. Due to factors such as its market environment and import fees, the price of each box of the Hong Kong version can even be as high as 90,000 yuan. Despite this, there are still some patients who choose this route because of their trust in the quality and efficacy of the drug. Because the Hong Kong version of drugs can guarantee supply and a more stable source of drugs in some cases, it has attracted the attention of many patients.
It should be noted that for patients taking giritinib, doctors will conduct genetic testing before treatment to confirmthe presence of FLT3 mutations, which is crucial for developing personalized treatment plans. In addition, during treatment, patients need to be monitored regularly to evaluate the efficacy and adverse reactions of the drug to ensure safe and effective use of the drug.
Reference materials:https://www.xospata.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)